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Abstract: In this work, novel docetaxel (DTX) -loaded Tween 80-free Pluronic P123 (P123) 
micelles with improved therapeutic effect were developed. The freeze-dried DTX-loaded 
P123 micelles (DTX-micelles) were analyzed by HPLC, TEM and DLS to determine the 
DTX loading, micelle morphology, size, respectively. The in vitro cytotoxic activity of 
DTX-micelles in HepG2, A549 and malignant melanoma B16 cells were evaluated by MTT 
assay. The corresponding in vivo antitumor efficacy was assessed in Kunming mice bearing 
B16  tumor  after  intravenous  administration.  The  DTX-loading  and  efficiency  into  the 
micelles were 2.12 ±  0.09% and 86.34 ±  3.32%, respectively. The DTX-micelles were 
spherical with a mean particle size of 50.7 nm and size distribution from 22 to 84 nm, which 
suggested that they should be able to selectively accumulate in solid tumors by means of 
EPR effect, with a zeta potential of −12.45 ±  3.24 mV. The in vitro release behavior of DTX 
from  DTX-micelles  followed  the  Weibull  equation.  Compared  with  Duopafei
®, 
DTX-micelles showed higher cytotoxicity against HepG2 (P < 0.01), A549 (P < 0.05) and 
B16 (P < 0.01) cells. In addition, DTX-micelles exhibited remarkable antitumor activity and 
reduced toxicity on B16 tumor in vivo. The tumor inhibition rates (TIR) of DTX-micelles 
was  91.6%  versus  76.3%  of  Duopafei
®  (P  <  0.01).  These  results  suggested  that  P123 
micelles might be considered as an effective DTX delivery system. 
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Taxoids,  paclitaxel (Taxol
®) and docetaxel (Taxotere
®), represent a novel class of antineoplastic 
drugs [1]. Docetaxel (DTX) is an inhibitor of microtubule depolymerization and has a broad antitumor 
activity against a variety of solid tumors [2], including breast [3–5], non-small cell lung cancer [6], 
ovarian [7] as well as gastric [8], head and neck [9], and prostate carcinomas [10]. 
However,  its clinical efficacy is limited due to its poor solubility, low selective distribution, fast 
elimination in vivo, etc. Presently, Taxotere
® and Duopafei
® contain a high concentration of nonionic 
surfactant polysorbate 80 (Tween 80
®) [11–13], which has been associated with several hypersensitivity 
reactions (e.g., fluid retention, neurotoxicity, musculoskeletal toxicity and neutropenia) [14,15]. In order 
to eliminate the Tween 80
®-based vehicle and in an attempt to increase the drug solubility, lately, a 
number of alternative formulations have been developed, including liposomes [16–18], nanoparticles [19], 
microemulsions [20,21], drug conjugates [22–24]. The rationale behind these approaches is to increase 
antitumor efficacy of DTX while reducing systemic side effects. 
In the past decade, polymeric micelles have been extensively studied for their prominent superiorities 
among  the  emerging  nano-scopic  carrier  systems  [25–27].  Polymeric  micelles  have  a  core-shell 
structure  with  diameters  typically  smaller  than  100  nm.  The  hydrophobic  core  can  serve  as  a 
microenvironment  for  incorporating  hydrophobic  drugs  such  as  anticancer  drugs  by  hydrophobic 
interaction. The hydrophilic outer shell serves as a stabilizing interface between the hydrophobic drug 
and  the  external  medium,  which  can  avoid  the  micelles  being  quickly  taken  up  by  the 
reticuloendothelial  system  (RES)  after  intravenous  administration.  It  provides  several  advantages 
including drug solubilization, controlled drug release, escaping from RES uptake, and tumor targeting 
by enhanced permeability and retention (EPR) effect [28,29]. 
Several  DTX-loaded  polymeric  micelles  had  been  studied,  including  poly(ethylene 
oxide)-block-poly(butylene/styrene  oxide)(PEO-b-P(SO/BO)  micelles  [30],  poly(ethylene 
glycol)-block-poly(epsilon-caprolactone)(PEG-b-PCL) micelles [31], and monomethoxy-poly(ethylene 
glycol)-block-poly(L-lactide)/DTX  (MPEG-b-PLLA/DTX)  conjugates  [24],  which  could  notably 
solubilize  and  protect  the  anticancer  drug  docetaxel  (DTX)  from  degradation.  However,  recent 
developments indicate that nanomaterials could not only serve as inert carriers, but also as biological 
response  modifiers.  One  representative  of  such  materials  is  Pluronic  block  copolymers  that  are 
amphiphilic synthetic polymers, composed of hydrophilic poly (ethylene oxide) (PEO) blocks and 
hydrophobic poly (propylene oxide) (PPO) blocks, arranged in triblock structure: PEO–PPO–PEO. 
Several Pluronic block copolymers are listed in U.S. Pharmacopoeia and are approved for various 
medical uses as formulation excipients [32]. Pluronic micelles represent a novel type of nanomedicines 
that can increase solubility, improve circulation time, and release drugs at the target sites. Furthermore, 
Pluronic molecules display important biological activities of their own. Specifically, they can inhibit 
P-glycoprotein  (P-gp),  a  drug  efflux  protein  that  hinders  distribution  of  many  drugs  to  the  brain, 
intestine, and multidrug-resistant (MDR) tumors [11,33,34]. 
The aim of this study was to develop a new Tween 80-free, polymeric micellar formulation for DTX, 
intended  to  be  intravenously  administered.  To  achieve  this  purpose,  Pluronic  P123 
(PEO20-PPO65-PEO20)  with  longer  hydrophobic  blocks,  which  was  chosen  for  its  commercial 
availability, biocompatibility and safety [35,36], was used to produce amphiphilic micelles for DTX. Int. J. Mol. Sci. 2011, 12                         
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Paclitaxel (PTX)-loaded P123 micelles were studied by Han et al. [34]. The results showed P123 
micelles may efficiently load, protect and retain PTX in the biological environment. Moreover, they 
could increase blood circulation time and reduce the distribution in the liver. 
DTX-loaded P123 micelles were prepared by thin-film hydration method [11]. The micelles were 
characterized in terms of morphology, particle size and zeta potential. In vitro drug release was assessed 
using the dialysis bag diffusion technique. In vitro cytotoxic activity of DTX-micelles was performed 
using HepG2, A549 and malignant melanoma B16 cells. Finally, in vivo tumor growth inhibition of 
DTX-micelles was also investigated in Kunming mice bearing B16-tumor. 
2. Results and Discussion 
2.1. Preparation of DTX-Micelles 
On the basis of optimization with single factors, orthogonal experiment design was employed for 
further optimization taking the entrapment efficiency as index. The  variables in our studies were as 
follows: the weight of DTX, the weight of P123, the volume of oil-phase and water-phase. 
The stability issue of polymeric micelles in vitro or in vivo has been an important challenge of micelle 
investigators  [37].  Lyophilisation  is  a  common  procedure  to  increase  the  long-term  stability  of 
pharmaceutical formulations. In order to avoid disaggregation of DTX-micelles in vitro, the micelles 
solutions were freeze-dried to store. With 2% manicol as a protective excipient, a brittle and white color 
lyophilized powder was gained. The lyophilization process with manicol was successfully applied for 
lyophilization of DTX-micelles formulations. The DTX loading in the micelle formulation was stable 
enough for clinical application. 
The  optimized  formulation  was  repeated  in  triplicate.  The  samples  were  analyzed  before 
lyophilization and after reconstitution. In the initial formulation, the DTX-loading and efficiency into 
the micelles were 2.35 ± 0.08% and 92.07 ± 1.77%, respectively. After lyophilization and reconstitution, 
the DTX-loading and efficiency into the micelles were 2.12 ±  0.09% and 86.34 ±  3.32%, respectively. 
The solubility of DTX in micelles was increased up to about 0.8 mg/mL. This concentration is high 
enough to be used in clinical studies (<0.74 mg/mL). 
2.2. Physicochemical Characterization of DTX-Micelles 
Figure  1A  shows  the  TEM  image  of  fresh-prepared  DTX-micelles,  which  indicates  that  the 
self-assembled micelles are well dispersed as individual particles with spherical shape. Furthermore, 
DTX-micelles were found to have an average diameter of 38.9nm and size distribution from 9 to 55 nm 
(Figure  2A)  and  the  zeta  potential  of  −10.56  ±  2.34  mV.  As  shown  in  Figure  1B,  freeze-dried 
DTX-micelles suspended in deionized water were still spherical with a mean particles size of 50.7 nm 
and size distribution from 22 to 84 nm (Figure 2B) and the zeta potential of −12.45 ±  3.24 mV. 
The  DLS  analysis  of  reconstituted  DTX-micelles  showed  only  a  small  size  increase  after  the 
lyophilization process, thus keeping the micellar carrier system. Moreover, the <100 nm diameter of 
polymeric micelles suggests that DTX-micelles should be able to selectively accumulate in solid tumors 
by means of EPR effect. 
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Figure 1. Transmission electron micrograms of DTX-micelles. (A) fresh-prepared micelles 
(× 72,000); (B) freeze-dried micelles (× 72,000). 
 
Figure  2.  Size  distribution  of  DTX-micelles  determined  by  DLS.  (A)  fresh-prepared 
micelles; (B) freeze-dried micelles. 
 
2.3. In Vitro Drug Release 
The in vitro release profile of DTX-micelles was investigated in PBS (phosphate buffer solution, 
pH 7.4) containing 0.5% Tween 80. The in vitro release behavior of DTX-micelles presented as the 
accumulative percentage release was shown in Figure 3. The release profiles of DTX-micelles were 
fitted with five different model equations, including zero-order kinetics, first-order kinetics, Higuchi 
equation, Weibull and Ritger-Peppas equations. The criterion for selecting the most appropriate model 
was  based on  best  goodness-of-fit  (R
2  values). The  results  showed  that the release of  DTX from 
DTX-micelles followed the Weibull equation: lnln(1/(1−Q/100)) = 0.738lnt − 1.796 (r = 0.9935). It was 
obvious that DTX released much slower from DTX-micelles than from Duopafei
®. The DTX-micelles 
released approximately 84.05% DTX during 24h, which was consistent with the release behavior of 
paclitaxel(PTX)-loaded P123 micelles [34]. In contrast, the release of DTX from Duopafei
® was faster 
and about 100% of the drug was released after being immersed for 24 h. 
Normally, three basic mechanisms, namely swelling/erosion, diffusion and degradation are present 
for the release of the loaded drug from polymeric particles [38]. Any or all of these mechanisms may 
occur in a given release system. The hydrophilicity of the polymer would determine the uptake speed of 
water during the course of release. With the uptake of water, the micelle particles would swell and allow 
the drug within to diffuse through the pores. The difference between the release behavior of DTX from 
Duopafei
® and DTX-micelles may be attributed to the fact that the drug was encapsulated into the core Int. J. Mol. Sci. 2011, 12                         
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of micelles [39]. The disintegration of the micelles after dilution was a relatively slow process. The drug 
released from micelles mainly through dissolution and diffusion. 
Figure 3. Accumulative DTX release from Duopafei
® and DTX-micelles in PBS (phosphate 
buffer solution, pH 7.4) containing 0.5% Tween 80 at 37 ±  0.5 °C  (n = 3). 
 
2.4. In Vitro Cytotoxic Activity 
The in vitro cytotoxic activity of Duopafei
®, blank micelles and DTX-micelles was assessed by MTT 
assay in HepG2, A549 and B16 cells. The half maximal inhibitory concentration (IC50) values were 
listed in Table 1. The range of concentrations of DTX was from 0.01–20 μM. The drug concentration 
played a major role in the in vitro cytotoxicity of DTX. DTX-micelles and Duopafei
® showed similar 
concentration-dependent growth inhibition for all cell lines. However, each cell line exhibited different 
sensitivities to DTX-micelles. HepG2 cells were the most sensitive to DTX-micelles, with an IC50 
value of 0.34 μM. DTX-micelles had decreased the IC50 values for all the cell lines with a statistical 
significance compared to Duopafei
®, indicating that DTX-micelles showed higher cytotoxicity against 
these cells. This decrease in IC50 can result from an inhibition of cell growth or cell cytotoxicity [40]. 
Micelles were associated with the cells and internalized together with the entrapped drug in the 
cytoplasm, probably via endocytic mechanism. The improved interaction and intracellular localization 
led to the increased cytotoxicity comparable to that of Duopafei
® [11]. 
Table 1. The half maximal inhibitory concentration values on HepG2, A549 and B16 cells 
incubated with Duopafei
®, DTX-micelles and Blank micelles at 96 h (n = 3). 
Treatment type 
IC50 values (μM) 
on HepG2 cells  on A549 cells  on B16 cells 
Duopafei
®  0.96 ±  0.05  0.74 ±  0.02  0.72 ±  0.10 
DTX-micelles  0.34 ±  0.02**  0.44 ±  0.05*  0.49 ±  0.08** 
Blank micelles  12.84 ±  0.12  29.62 ±  1.02  13.79 ±  0.24 
Note: * P < 0.05, ** P < 0.01 versus Duopafei
®. Int. J. Mol. Sci. 2011, 12                         
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2.5. In Vivo Tumor Growth Inhibition Study 
The in vivo antitumor effect of DTX-micelles was assessed by intravenous administration using 
Kunming mice bearing B16 tumor as the model animals. The treatments were injected via the tail vein 
once a week for three weeks. Figure 4A shows changes of tumor volumes. It was found that the tumor 
volumes  of  DTX-micelles  group  were  smaller  than  those  of  Duopafei
®  group,  indicating  that 
DTX-micelles might more effectively inhibit tumor growth. It should be noted that the difference in 
tumor volumes among the groups of DTX-micelles and blank micelles as well as saline was highly 
significant (P < 0.01). Figure 4B shows typical photographs of excised sarcomas from the tested groups, 
which provide a direct visual representation of the tumor-suppression effect. 
Table  2 lists the tumor inhibition rates of all the tested groups. The DTX-micelles group showed 
significant tumor inhibition rates (TIR = 91.6%). The weights of excised tumor mass were shown in 
Figure 4C (P < 0.05, DTX-micelles group versus Duopafei
® group). Figure 4D shows the variation of 
relative body weight of the mice with time. The results indicated that the mice experienced a slight 
weight loss of either DTX-micelles group or Duopafei
® group, while the  extent  of  weight  loss  of 
DTX-micelles was much smaller than that induced by Duopafei
®. The analysis of body weight variations 
can be used to define the systemic toxicity. These results lead to a conclusion that DTX-micelles generate 
less toxicitiy to normal organs than Duopafei
® when administered intravenously. Moreover, we also 
observed that the mice receiving Duopafei
® were in a weak state, in the aspects of movement and spirit, 
whereas no obvious alteration was observed in the micelles-treated animals. 
Figure 4. The in vivo antitumor effect of DTX-micelles. (A) the changes of tumor volumes 
of the tested groups; (B) the typical photographs of excised sarcomas from the tested groups; 
(C) the weights of excised tumor mass; (D) the variation of relative body weight of the mice 
with time. * P < 0.05, ** P < 0.01 versus Duopafei
®.  
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Table 2. The in vivo antitumor effects in B16 bearing mice (n = 6). 
Formulation 
Tumor weight 





Saline  12.18 ±  3.20  N.A.  N.A. 
Blank micelles  10.43 ±  3.59  14.4  N.A. 
Duopafei
®  2.89 ±  2.04  76.3  <0.01 
DTX- micelles  1.02 ±  0.91  91.6  <0.01 
a P value in the t-test denoting statistical significance. 
In brief, it was shown that the antitumor efficacy of DTX-micelles was greatly superior to that of 
Duopafei
® in B16 tumor bearing mice model, which was consistent with the in vitro cytotoxicity test 
above. When encapsulated into micelles, DTX could reach the solid tumor site through EPR effect and 
maintain the effective therapeutic concentration for a longer period of time. The unique core-shell 
architecture of polymeric micelles with a diameter of several tens of nanometers might allow prolonged 
blood circulation and preferential accumulation in solid tumors [41–43]. 
The use of polymeric micelles as drug carrier may reduce the toxicity of the incorporated drug. In 
general, the toxicity of the whole formulation is investigated while results of the micelles itself are not 
described. So, there should be a specific emphasis on the toxicity of the ―empty‖ non-drug loaded 
micelles. This is especially important when slowly or non-degradable micelles are used for drug delivery 
which may show persistence and accumulation on the site of the drug delivery, eventually resulting in 
chronic inflammatory reactions [44]. The results of an in vitro cytotoxicity test and in vivo tumor growth 
inhibition  study  showed  that  P123  micelles  itself  had  a  certain  toxicity,  which  may  be  due  to 
non-degradable micelles accumulated in vivo. The real reasons are unknown. Understanding clearance 
kinetics of P123 micelles would be important in understanding their potential for adverse effects. It is 
encouraging that DTX-micelles possess greater efficiency to solid tumors and less toxicity to normal 
organs than Duopafei
® in this work. It is worthy of further study for clinical application. The micelles 
formulations allowed stopping usage of Tween 80 which causes serious hypersensitivity reactions. 
3. Materials and Methods 
3.1. Materials 
Pluronic P123 (P123) was purchased from Sigma (China). DTX and Duopafei
® were obtained from 
Qilu Pharmaceutical Co., Ltd (Jinan, China). Ultra-purified water was used throughout. All reagents for 
HPLC analysis, including acetonitrile and methanol were of HPLC grade. Other chemicals and reagents 
were of analytical grade, obtained commercially. 
Human  hepatocellular  liver  carcinoma  (HepG2),  lung  adenocarcinoma  (A549)  and  murine 
malignant melanoma (B16) cell line were obtained from Shandong Institute of Immunopharmacology 
and  Immunotherapy  (Shandong,  China).  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl  tetrazolium 




Female  Kunming  mice  (18–22  g)  were  supplied  by  Laboratory  Animals  Center  of  Shandong 
University, Jinan, China. The animals were used following the guidelines of the Ethical Committee for 
Animal Experiments of Shandong University. The animals were acclimatized at a temperature of 
25 ±  2 °C  and a relative humidity of 70 ±  5% under natural light/dark conditions for at least 24 h 
before dosing. 
3.3. Preparation of DTX-Micelles 
DTX-micelles were prepared by thin-film hydration method [11]. Briefly, 4 mg DTX and 150 mg 
P123 were dissolved in 3 mL acetonitrile in a round-bottom flask. The solvent was removed by rotary 
evaporation at 40 °C  for about 30 minutes to obtain a solid DTX/copolymer matrix. Residual acetonitrile 
was removed under vacuum overnight at room temperature. Then, the resultant thin film was hydrated 
with 5 mL water at 40 °C , then stirred at 500 rpm for 1 h to obtain a clear micellar solution, which was 
filtered  through  0.22  μm  filters  (Millipore)  to  remove  the  non-encapsulated  drug,  followed 
by lyophization. 
3.4. Determination of Docetaxel Content in Micelles 
The  drug  concentration  was  determined  by  RP-HPLC  method  (SPD-10Avp  Shimadzu  pump, 
LC-10Avp Shimadzu UV-vis detector). A 65:35 (v/v) degassed mixture of acetonitrile and water was 
used as the mobile phase. The reverse phase column was Venusil XBP C-18. The column temperature 
was maintained at room temperature. The flow rate was set at 1.0 mL/min and the samples were 
monitored at 230 nm [19]. Sample solution was injected at a volume of 20 μL. The HPLC was calibrated 
with standard solutions 5 to 50 μg/mL of DTX dissolved in acetonitrile (correlation coefficient r = 0.9998). 
Micelles were dissolved in acetonitrile and vortexed to get a clear solution. Drug-loading (DL%) and 
encapsulation efficacy (EE%) were calculated by the following equations [11]: 
100%
drug and polymer feeding the of weight
micelles in drug the of weight
DL%     (1)  
100%
drug feeding the of weight
micelles in drug the of weight
EE%     (2)  
3.5. Physicochemical Characterization of DTX-Micelles 
Transmission electron microscope (TEM) was performed to evaluate the surface morphology of 
micelles after negative staining with phosphotungstic acid solution (2%, w/v)[45]. The mean particle 
size and size distribution of the micelles were determined by dynamic light scattering (DLS)(Zetasizer 
3000SH, Malvern Instruments, UK). Zeta potential was measured by the Laser Doppler Anemometry 
(LDA) on ZetaPlus Zeta Potential Analyzer (Brookheaven Instruments Corporation). The lyophilized 
DTX-micelles were reconstituted in water, and were analyzed for size by DLS, for morphology by TEM, 
for drug loading by HPLC. All measurements were performed at 25 °C . Experimental values were 
calculated from the measurements performed at least in triplicate. Int. J. Mol. Sci. 2011, 12                         
 
1692 
3.6. In Vitro Release Studies 
In vitro release of DTX from the polymeric micelles were carried out in an aqueous release medium 
(PBS, pH 7.4) containing 0.5% Tween 80 (w/v) to enhance the solubility of DTX [20], using the dialysis 
bag diffusion technique. First, aliquots of DTX-micelles and Duopafei
® were placed into the pre-swelled 
dialysis bags with 8–14 kDa molecular weight cutoff, and were immersed in 15 mL of release medium in 
screw-capped tubes, which were placed in a horizontal shaker bath maintained at 37 ± 0.5 °C  and shaken 
at 100 rpm. At fixed time intervals, the dialysis bags were taken out and re-placed into new containers 
filling with 15 mL fresh medium. The concentrations of DTX in the samples withdrawn from the 
incubation  medium  were  analyzed  by  HPLC  as  described  above.  Sink  condition  was  maintained 
throughout  the  release  period.  Data  obtained  in  triplicate  were  analyzed  graphically  (the  percent 
accumulative amount of DTX released from micelles versus time plotted). 
3.7. In Vitro Cytotoxic Activity 
The in vitro cytotoxic activity of DTX-micelles was tested in HepG2, A549 and B16 cells using the 
MTT assay [46]. Briefly, cells were seeded in 96-well plates at the density of 4000 viable cells per 
well and incubated 24 h to allow cell attachment. Cells were then treated with a series of doses of 
Duopafei
®, blank micelles, or DTX-micelles, respectively, at 37 °C . After 96 h of incubation, 20 μL of 
MTT (5 mg/mL) was added to each well of the plate. After incubating for additional 4 h, MTT was 
aspirated off and 200 μL/well of DMSO was added to dissolve the formazan crystals. Absorbance was 
measured  at  570  nm  and  630  nm  by  a  microplate  reader  (FL600,  Bio-Tek  Inc.,  Winooski,  VT). 
Untreated cells were taken as control with 100% viability and cells without addition of MTT were used 
as blank to calibrate the spectrophotometer to zero absorbance [47]. The results were expressed as 
mean values ±  standard deviation of 3 measurements. 
3.8. In Vivo Tumor Growth Inhibition Study 
Kunming mice implanted with B16 cells were used to qualify the relative efficacy of DTX-micelles 
through intravenous administration. The mice were raised under specific pathogen-free circumstances 
and all of the animal experiments were performed in full compliance with guidelines approved by the 
Animal Care Committee of Shandong University. 
The mice were subcutaneously injected at the right axillary space with 0.1mL of cell suspension 
containing 5 ×  10
4 B16 cells. Treatments were started after 9–10 days of implantation. The mice with 
tumor volume of about 100 mm
3 were selected and this day was designated as ‗Day 0‘. 
On Day 0, the mice were randomly divided into four groups (6 mice per group): group1: saline; 
group 2: blank micelles; group 3: Duopafei
® (DTX concentration of 20 mg/kg; diluted in saline); group 4: 
DTX-micelles (DTX concentration of 20mg/kg; diluted in saline). The treatments were injected via the 
tail vein once a week for three weeks. All mice were tagged, and tumors were measured every other day 
with calipers during the period of study. The tumor volume was calculated by the formula (W
2× L)/2, 
where W is the tumor measurement at the widest point and L stands for the tumor dimension at the 
longest point. Each animal was weighed at the time of treatment, so that dosages could be adjusted to Int. J. Mol. Sci. 2011, 12                         
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achieve the mg/kg amounts. Animals were weighed every other day throughout the experiments. The 
body weights of mice were monitored as an index of systemic toxicity [48,49]. 
At the end of the experiment, the animals were killed, and the tumor mass was harvested, weighed 
and photographed. The tumor inhibition ratio (TIR) was calculated according to the follow equation: 
TIR(%) = ((Wc−Wt)/Wc) ×  100%, wherein Wc and Wt represent the mean tumor weight of control group 
and treatment group, respectively. 
3.9. Statistical Analysis 
All results are expressed as mean ±  standard deviation. Paired Students‘s t-test or ANOVA analyses 
were performed to demonstrate statistical differences (P < 0.05). 
4. Conclusions 
The objective of this study was to design Tween 80-free micelles loaded with the poorly soluble 
anticancer drug DTX. DTX was well incorporated into P123 micelles with high drug-loading coefficient 
and encapsulation efficacy. The obtained micelles had a spherical shape with a hydrodynamic diameter 
of  about  50  nm.  Cytotoxicity  test  against  HepG2,  A549  and  mouse  B16  cells  showed  that 
DTX-micelles had better in vitro cytotoxicity than Duopafei
®. Furthermore, the in vivo antitumor effect 
was investigated. It was found that DTX-micelles also exhibited superior in vivo antitumor effect when 
compared to the commercially available DTX injection. These results provide evidence for the clinical 
superiority  of  this  micellar  formulation,  which  has  demonstrated  a  better  therapeutic  index  than 
Duopafei
®. Furthermore, this work has been completed as part of a patent application. In future studies, 
it is planned to use tumor models that are more sensitive to DTX, such as human breast cancer (MCF-7), 
in athymic nude mice. Taken together, P123 micelles have a promising future in clinical application. 
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